Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA )

0.6070 +0.0443 (+7.87%)
Streaming Delayed Price Updated: 1:58 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 249,971
Open 0.5990
Bid (Size) 0.6000 (32)
Ask (Size) 0.6094 (6)
Prev. Close 0.5627
Today's Range 0.5736 - 0.6198
52wk Range 0.0541 - 3.030
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire

Performance

YTD
-31.02%
-31.02%
1 Month
-24.13%
-24.13%
3 Month
-1.30%
-1.30%
6 Month
+425.09%
+425.09%
1 Year
-64.50%
-64.50%

More News

Read More
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Via Benzinga
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
From ZyVersa Therapeutics
Via GlobeNewswire
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
What In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?
Via Benzinga
US Stocks Edge Higher; Domino's Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Intuitive Machines (LUNR) Stock Down 23% Today?
Via InvestorPlace
Why Is Aclarion (ACON) Stock Down 19% Today?
Via InvestorPlace
Why Is Freight Technologies (FRGT) Stock Up 25% Today?
Via InvestorPlace
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
From ZyVersa Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.